Clinical Trials
13 trialsNCT04934514 2024-02-20
Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 1/2 Unknown
NCT06008366 2023-09-13
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT06008379 2023-09-13
A Study of 7MW3711 in Subjects With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05840835 2023-08-08
IMMINENT-01
Immix Biopharma, Inc.
Phase 1/2 Unknown
NCT05173805 2023-07-18
Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1/2 Unknown
NCT05944185 2023-07-14
Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors
Shanghai Cell Therapy Group Co.,Ltd
Phase 1/2 Unknown
NCT05794477 2023-06-02
A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT05805956 2023-04-10
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Unknown
NCT05434299 2023-03-16
A Study of TFX05-01 in Patients With Advanced Solid Tumors
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase 1/2 Unknown
NCT05645315 2022-12-09
Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT05258266 2022-03-14
A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors
Nanjing Zenshine Pharmaceuticals
Phase 1/2 Unknown
NCT05119933 2021-11-15
A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1/2 Unknown
NCT04337463 2021-05-17
ATG-008 Combined With Toripalimab in Advanced Solid Tumors
Sichuan University
Phase 1/2 Unknown